Analyst Comment

Curasight: Præsentation af Q1 2026 resultater (Optagelse)

Hvis du ikke deltog i eventet i dag, eller gerne vil se præsentationen igen med Curasights CEO Ulrich Krasilnikoff og CSO Andreas Kjær, kan du se hele præsentationen her:

Curasight . Q1 2026 Event

Fokus på eventet var udover kvartalet resultater blandt andet rettet mod den seneste tids nyhedsstrøm for både uTRACE® og uTREAT®, hvad man kan forvente af nyheder i den kommende tid fra pipelinen, samt strategiske overvejelser omkring partnerskaber.

Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR abonnementsaftale/Michael Friis 29/05-2026 - kl. 14:56.

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.